Talimogene laherparepvec in melanoma: Added benefit not proven
Talimogene laherparepvec (trade name: Imlygic) has been approved since December 2015 for adults with advanced melanoma. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment ...
Oct 6, 2016